Targeting Poor Proteasomal Function with Radioiodine Eliminates CT26 Colon Cancer Stem Cells Resistant to Bortezomib Therapy

Overview

Journal Sci Rep

Specialty Science

Date 2020 Sep 2

PMID 32868872

Authors

Jin Hee Lee

Kyung-Ho Jung

Jin Won Park

Seung Hwan Moon

Young Seok Cho

Kyung-Han Lee

Affiliations

Soon will be listed here.

Abstract

We tested the hypothesis that tumor response to conventional bortezomib (BTZ) treatment is enhanced by targeted radiotherapy of resistant cancer stem cells (CSCs) that have characteristically poor proteasome function. This was accomplished by augmenting I uptake through expression of a sodium-iodide symporter (NIS) fusion protein that accumulates in cells with low proteasome activity. The NIS gene fused with the C-terminal of ornithine decarboxylase degron (NIS-cODC) was cloned. Stably expressing CT26/NIS-cODC cells and tumorsphere-derived CSCs were evaluated for NIS expression and radioiodine uptake. CT26/NIS-cODC cells implanted into mice underwent PET imaging, and tumor-bearing mice were treated with BTZ alone or with BTZ plus I. CT26/NIS-cODC cells accumulated NIS protein, which led to high radioiodine uptake when proteasome activity was inhibited or after enrichment for stemness. The cell population that survived BTZ treatment was enriched with CSCs that were susceptible to I treatment, which suppressed stemness features. Positron emission tomography and uptake measurements confirmed high I and I uptake of CT26/NIS-cODC CSCs implanted in living mice. In CT26/NIS-cODC tumor-bearing mice, whereas BTZ treatment modestly retarded tumor growth and increased stemness markers, combining I therapy suppressed stemness features and achieved greater antitumor effects. The NIS-cODC system offer radioiodine-targeted elimination of CSCs that are tolerant to proteasome inhibition therapy.

References

Hussain S, Singh A, Nazir S, Tulsyan S, Khan A, Kumar R . Cancer drug resistance: A fleet to conquer. J Cell Biochem. 2019; 120(9):14213-14225. DOI: 10.1002/jcb.28782. View

Dean M . Cancer stem cells: Implications for cancer causation and therapy resistance. Discov Med. 2010; 5(27):278-82. View

Steinbichler T, Dudas J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova I . Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018; 53:156-167. DOI: 10.1016/j.semcancer.2018.11.006. View

Lee M, Lopez-Diaz F, Khan S, Tariq M, Dayn Y, Vaske C . Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc Natl Acad Sci U S A. 2014; 111(44):E4726-35. PMC: 4226127. DOI: 10.1073/pnas.1404656111. View

Kurtova A, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner S . Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2014; 517(7533):209-13. PMC: 4465385. DOI: 10.1038/nature14034. View

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T . Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018; 173(4):879-893.e13. PMC: 6132060. DOI: 10.1016/j.cell.2018.03.041. View

Hata A, Niederst M, Archibald H, Gomez-Caraballo M, Siddiqui F, Mulvey H . Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016; 22(3):262-9. PMC: 4900892. DOI: 10.1038/nm.4040. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

Dobbelstein M, Moll U . Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 2014; 13(3):179-96. DOI: 10.1038/nrd4201. View

10.

Chen L, Madura K . Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 2005; 65(13):5599-606. DOI: 10.1158/0008-5472.CAN-05-0201. View

11.

Loda M, Cukor B, Tam S, Lavin P, Fiorentino M, Draetta G . Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997; 3(2):231-4. DOI: 10.1038/nm0297-231. View

12.

Oren M, Kotler E . p53 mutations promote proteasomal activity. Nat Cell Biol. 2016; 18(8):833-5. DOI: 10.1038/ncb3392. View

13.

Nalepa G, Rolfe M, Harper J . Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov. 2006; 5(7):596-613. DOI: 10.1038/nrd2056. View

14.

Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4(5):349-60. DOI: 10.1038/nrc1361. View

15.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O . Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10):944-53. DOI: 10.1056/NEJMoa1412096. View

16.

Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348(26):2609-17. DOI: 10.1056/NEJMoa030288. View

17.

Roeten M, Cloos J, Jansen G . Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol. 2017; 81(2):227-243. PMC: 5778165. DOI: 10.1007/s00280-017-3489-0. View

18.

Kirshner J, Thulien K, Martin L, Debes Marun C, Reiman T, Belch A . A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008; 112(7):2935-45. DOI: 10.1182/blood-2008-02-142430. View

19.

Voutsadakis I . Proteasome expression and activity in cancer and cancer stem cells. Tumour Biol. 2017; 39(3):1010428317692248. DOI: 10.1177/1010428317692248. View

20.

Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M . Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer. 2014; 14:152. PMC: 3975871. DOI: 10.1186/1471-2407-14-152. View